Anti-Human Siglec-2/CD22 Recombinant Antibody (RFB-4), PE (HB011327)

Name: Anti-Human Siglec-2/CD22 Recombinant Antibody (RFB-4), PE
Brand: abinScience
SKU: HB011327
Price: 290 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

50T
100T

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HB011327
Reactividad de especies	Human
Aplicaciones	ELISA, FCM
Especie huésped	Mouse
Clonalidad	Monoclonal
Isotipo	IgG1, kappa
ID de clon	RFB-4
Conjugación	PE
Aplicaciones probadas	FCM
Objetivo	B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, CD22, SIGLEC2, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
Nivel de endotoxinas	Please contact with the lab for this information.
Pureza	>90% as determined by SDS-PAGE.
Productos asociados	Mouse IgG1, kappa Recombinant Isotype Control Antibody (MOPC-21), PE
Número de acceso	P20273
Forma	Liquid
Buffer de almacenamiento	0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Store at 4°C for 12 months. Protect from light. Do not freeze.
Fondo	B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa). 1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755 2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166 3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905 4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366
Nota	For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only.

Imágenes

Flow CytoMetry

Flow-cytometry using PE anti-human CD22 antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an PE anti-human CD22 monoclonal antibody (Catalog: HB011327, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.

Referencias

Datasheet